News

We are excited to enter the China market, which represents a continuation of our efforts to expand our international footprint in key markets where breast-care is increasingly becoming

The two partners will establish a joint research center at Tsinghua University, the Bayer-Tsinghua (Institute of Biomedicine) Research Center of Innovative Drug Discovery. Yigong Shi, a structural biologist,

As one of the first companies to file an abbreviated new drug application containing a paragraph IV certification for this product, Teva has been awarded a 180-day period

Delivering comprehensive data capture for both general and vascular procedures, the Interventional Radiology module automatically documents Joint Commission on Accreditation of Healthcare Organizations and patient safety performance measures.

The Year Ended December 31, 2008 Year 2008 revenue growth came from $1.59 million of increased product revenues and $.23 million of increased research and grant revenues. The

Helix BioPharma, a Canada-based biopharmaceutical company, has received the necessary regulatory approvals in Germany to initiate its planned Phase II pharmacokinetic study of topical interferon alpha-2b in patients

Australia-based biotechnology company Avexa has announced positive data from the ongoing Phase IIb clinical trial of apricitabine. After 96 weeks of treatment, no signature resistance to ATC has

The initial term of the agreement is five years totaling more than $3 million over the life of the agreement, assuming successful completion of the development of the

BioAlliance Pharma, a specialty pharmaceutical company, has received E6.4m in funding from OSEO, the French state innovation agency. The company will devote the funds to the development of